Day: September 27, 2023

VANCOUVER, British Columbia, Sept. 27, 2023 (GLOBE NEWSWIRE) — NorthWest Copper Corp. (TSXV: NWST) (OTCQX: NWCCF) (“NorthWest” or the “Company”) is pleased to provide an update on the transition of the Company under the stewardship of its newly elected Board of Directors (the “Board”). The Board has elected Mr. Grant Sawiak as its Chair. The Board will be working closely with existing management to address the concerns of the shareholders and to move the Company forward in the interest of all stakeholders. To this end, the Board has formed a Technical Committee comprising Messrs. Jim Steel and John Theobald to urgently review all available technical information of NorthWest’s Copper properties (the “Projects”). The Technical Committee will work with senior management to recommend the Company’s technical strategy that will ensure...

FINANCIAL RELEASE September 27th, 2023  Aéroports de Paris SAGroupe ADP took note of the French government’s proposal for a new tax applicable to certain major transport infrastructure in France, including ADP SA’s Groupe ADP took note of the finance bill for 2024, adopted today by the Council of Ministers. The bill plans to introduce a new tax applicable to certain French transport infrastructure companies, including Aéroports de Paris SA (ADP SA). The bill provides for a 4.6% tax applicable to the revenue, as stated in Aéroport de Paris SA’s annual accounts, notably excluding revenues from airport safety and security services, and after the deduction of a 120 million euros exemption. The tax base would therefore have been 2,175 million euros as of December 31st, 20221 (to be compared with 2022 consolidated revenue of...

Planegg/Martinsried, September 27, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued a patent (EP3 433 269) by the European Patent Office protecting its PD1-41BB costimulatory switch protein (CSP) technology. Medigene’s PD1-41BB CSP was developed by its partner Helmholtz Munich and is exclusively licensed to Medigene. “We are delighted to have been granted the European Patent for our PD1-41BB CSP, one of the key technologies of Medigene’s End-to-End (E2E) Platform. This complements our PD1-41BB IP-portfolio with similar patents already granted in the United States, China and Japan, and strengthens our patent portfolio worldwide,” said Selwyn Ho,...